Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

NCT00633789 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

597

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer
Transitional Cell Carcinoma
Soft Tissue Sarcoma
Gastric/Esophageal Adenocarcinoma
Pancreatic Cancer Including Ampulla of Vater

Interventions

DRUG: brivanib
DRUG: Placebo

Sponsor

Bristol-Myers Squibb